Dr. Arnold Chin’s research focuses on understanding how the immune system recognizes tumors in order to harness these pathways to develop novel immune-based therapeutics towards bladder and prostate cancer. Recent work in the laboratory investigated the role of Toll-like receptor 3 (TLR3) in prostate cancer tumor surveillance and utilized agonists of TLR3 in the form of double-stranded RNA in a murine model of prostate cancer immunotherapy. Current research involves understanding the mechanisms of TLRs in anti-tumor activity and developing agonists of these receptors for use in clinical trials. Chin’s laboratory is also examining a Listeria monocytogenes-based vector that can selectively express tumor antigens for use in tumor vaccines. Initially developed in a prostate cancer model, they are adapting its use in a bladder cancer model.
Selected Cancer-Related Publications:
Finley DS, Pouliot F, Chin AI, Shuch B, Pantuck AJ, Belldegrun AS, Dekernion JB. Immunological therapy in urological malignancy: novel combination strategies. Int J Urol. 2011 Feb;18(2):94-101. Epub 2010 Nov 12
Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo B, Dempsey PW, Cheng G. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res. 2010 Apr 1;70(7):2595-603. Epub 2010 Mar 16.
Chin AI, Belldegrun AS. New perspectives in the treatment of prostate cancer. International Handbook of Prostate Cancer, 3rd Edition, Euromed Communications Ltd, 2008.
Chin AI, Dave DS, Rajfer J. Is repeat biopsy for isolated high-grade prostatic intraepithelial neoplasia necessary? Rev Urol. 2007 Summer;9(3):124-31.
Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 2006 Winter;8(1):1-7.